[Photo News] Leading pharma giants unveil cutting-edge oncology research at ASCO 2024
2024-06-02 Lee Han-soo
CHICAGO, Ill. -- By Lee Han-soo/Korea Biomedical correspondent –The American Society of Clinical Oncology (ASCO) 2024 Annual Meeting has drawn significant attention in the cancer research community as it kicked off its four-day meeting on Friday. Pharmaceutical companies worldwide have gathered to showcase and evaluate the potential success of their products at the convention.
ASCO is a premier global oncology conference, established in 1964, and recognized as one of the top three cancer conferences in the world. Held annually in Chicago at the McCormick Place, this event gathers oncology professionals, including pharmaceutical and biotech R&D experts, licensing professionals, oncologists, and regulatory officials from across the globe.
According to the organizers, over 500 exhibitors and 40,000 attendees will participate in the exhibition this year. The meeting also saw over 2,500 posters presented throughout the event and over 250 oral abstract presentations.
A glimpse at the multinational companies' booths at ASCO 2024 highlights the grand scale of this year's event.
The American Society of Clinical Oncology (ASCO) 2024 Annual Meeting kicked off its four-day run at the McCormick Place Convention Center in Chicago, Ill., on Friday (local time)
AbbVie plans to present new data from its antibody-drug conjugate (ADC) platform at the ASCO 2024, highlighting the potential of their ADCs targeting biomarkers such as c-Met and SEZ6 to deliver potent anti-cancer agents. Preliminary data from the phase 1 study of ABBV-400 in colorectal cancer (CRC) patients showed promising antitumor activity, particularly in those with higher c-Met expression, while ABBV-706 demonstrated a significant objective response rate in small cell lung cancer (SCLC) and neuroendocrine neoplasms (NENs).
Amgen will announce 17 abstracts at the ASCO 2024 Annual Meeting, highlighting innovations in treating difficult-to-treat cancers. A late-breaking oral presentation from the phase 3 CodeBreaK 300 study will report overall survival results for Lumakras plus Vectibix in KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Astellas Pharma will present 16 abstracts at the 2024 ASCO Annual Meeting, showcasing new research from its portfolio of approved and investigational cancer therapies, emphasizing targeted treatments for hard-to-treat cancers like prostate, urothelial, and gastric/gastroesophageal junction (GEJ) cancers. Highlights ｉｎｃｌｕｄｅ data from the phase 3 EV-302 trial on enfortumab vedotin combined with pembrolizumab in urothelial carcinoma, and final overall survival results from the phase 3 SPOTLIGHT study on zolbetuximab in gastric or GEJ adenocarcinoma.
AstraZeneca will present data from over 100 abstracts at the ASCO 2024 Annual Meeting, highlighting advancements in oncology, including two late-breaking plenary presentations. Key trials include the LAURA phase 3 trial of Tagrisso in unresectable, stage 3 EGFR-mutated NSCLC after chemoradiotherapy, and the ADRIATIC phase 3 trial of Imfinzi in limited-stage small cell lung cancer (LS-SCLC) post-chemoradiotherapy. Additionally, the DESTINY-Breast06 phase 3 trial will showcase Enhertu's efficacy in metastatic HR-positive, HER2-low, and HER2-ultralow breast cancer, reinforcing AstraZeneca's commitment to redefining cancer care.
Bristol Myers Squibb will present data from a variety of studies at the 2024 ASCO Annual Meeting. Key presentations include progression-free survival and overall response rate data from the phase 3 KRYSTAL-12 study of Krazati in KRASG12C-mutated non-small cell lung cancer (NSCLC), and overall survival benefits from the phase 3 CheckMate-9DW trial of Opdivo plus Yervoy in advanced hepatocellular carcinoma (HCC). Additionally, long-term data from the RELATIVITY-047, CheckMate-9LA, and CheckMate-816 trials highlight sustained responses and durable survival benefits in various NSCLC and melanoma settings.
Eisai will present research from its oncology portfolio and pipeline at the ASCO 2024 Annual Meeting, highlighting the pivotal phase 3 CLEAR/KEYNOTE-581 trial of Lenvima plus Keytruda in advanced renal cell carcinoma. Key presentations include biomarker analyses and disease progression patterns from this trial, as well as phase 3 data from the EMERALD study evaluating Herceptin and Perjeta with eribulin mesylate or a taxane in HER2-positive breast cancer.
Johnson & Johnson will present 34 clinical studies and real-world evidence presentations from its oncology portfolio at the 2024 ASCO Annual Meeting, featuring pivotal trials and updated clinical data in lung, prostate, and bladder cancers. Key presentations include late-breaking results from the phase 3 PALOMA-3 study of subcutaneous Rybrevant with Leclaza in EGFR-mutant NSCLC, data from the phase 2 PALOMA-2 study on the same combination as a first-line treatment, and subgroup analysis from the phase 3 MARIPOSA study.
GSK will present findings from 25 abstracts at the 2024 ASCO Annual Meeting, showcasing advancements in blood cancers, gynecologic cancers, and certain solid tumors. Highlights include pivotal data from the DREAMM-8 and DREAMM-7 phase 3 trials on Blenrep combinations in multiple myeloma and updated results for Jemperli in locally advanced mismatch repair deficient rectal cancer.
Eli Lilly will present data on Verzenio, Retevmo, olomorasib, and imlunestrant at the 2024 ASCO Annual Meeting. Highlights include outcome data from the phase 3 postMONARCH study of Verzenio in HR+, HER2- advanced breast cancer, results from the LIBRETTO-121 study of Retevmo in pediatric patients with RET-altered advanced solid tumors, and updated phase 1/2 data on olomorasib in KRAS G12C-mutant advanced cancers.
Merck, also known as MSD outside of U.S. and Canada, will present new data on four approved oncology medicines and four pipeline candidates across more than 25 cancer types at the 2024 ASCO Annual Meeting. Key presentations for Keytruda include three-year follow-up data from the KEYNOTE-966 study in advanced biliary tract cancer, long-term results from the KEYNOTE-859 study in HER2-negative gastric cancer, and patient-reported outcomes from the KEYNOTE-A39/EV-302 trial in metastatic urothelial cancer.
Moderna plans to present three abstracts on mRNA-4157 (V940), an investigational mRNA individualized neoantigen therapy, at the 2024 ASCO Annual Meeting. These include a poster on the INTerpath-001 study comparing V940 plus Keytruda to Keytruda with placebo in high-risk stage II-IV melanoma, a poster on the INTerpath-002 study design for V940 plus Keytruda versus placebo in early-stage NSCLC, and a rapid oral session presenting a three-year update from the KEYNOTE-942 trial on V940 plus Keytruda in resected melanoma. Moderna and Merck are jointly developing the studies.
Pfizer will present over 50 abstracts at the 2024 ASCO Annual Meeting, showcasing advancements in oncology, including 11 oral presentations across key tumor areas and scientific modalities. Highlights include five-year progression-free survival results from the phase 3 CROWN study of Lorbrena in ALK-positive advanced non-small cell lung cancer, and late-breaking results from the phase 3 ECHELON-3 study of Adcetris in relapsed/refractory diffuse large B-cell lymphoma.
Novartis plans to announce a variety of abstracts at the 2024 ASCO Annual Meeting. Key presentations include primary results from the ASC4FIRST phase 3 trial of Scemblix in newly diagnosed chronic myeloid leukemia, updates from the NATALEE trial of Kisqali in node-negative early breast cancer, and findings from the PSMAfore study of Pluvicto in metastatic castration-resistant prostate cancer.
Lunit, a Korean medical AI imaging company, will present seven studies at the ASCO 2024 Annual Meeting, showcasing AI-powered innovations in cancer diagnostics and therapeutics, including HER2 ultra-low expression identification in breast cancer and a model integrating chest CT and histopathology analysis for predicting immunotherapy response in NSCLC.
Korea National Enterprise for Clinical Trials (KoNECT) hosted a Korean pavilion at ASCO, showcasing the country's clinical trial capabilities. Eleven institutions, such as Hanmi Pharm, GCCL, Seoul National University Hospital, GI Innovation, and Quirent, participated this year. KoNECT will provide promotional and business meeting spaces for participating Korean companies, facilitating global partnerships and supporting the advancement of domestic clinical trials and new drug development.
Elevar Therapeutics, a majority-owned subsidiary of HLB, will present the overall survival analysis of camrelizumab and rivoceranib as a first-line treatment for unresectable hepatocellular carcinoma (uHCC).